CONTERA PHARMA A/S: Financial statements 2012
CVR: 33062214
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK -3,689,746 and a net result of DKK -4,245,465. Equity in the 2012 report amounted to DKK 6,401,686. The solvency ratio was 94.8%.
- Gross Profit
- DKK -3,689,746
- Profit/Loss
- DKK -4,245,465
- Equity
- DKK 6,401,686
- Total Assets
- DKK 6,750,389
Official annual report
Keep an eye on CONTERA PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of October 2, 2012, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has been appointed auditor of CONTERA PHARMA A/S.
As of October 2, 2012, EY Godkendt Revisionspartnerselskab has stepped down as auditor of CONTERA PHARMA A/S.
As of April 18, 2012, Carsten Schou has joined the board of directors of CONTERA PHARMA A/S.
As of April 18, 2012, Gunnar Magnus Severus Modee Persson has joined the board of directors of CONTERA PHARMA A/S.
As of April 18, 2012, Frank Knudsen has left the board of directors of CONTERA PHARMA A/S.
As of April 18, 2012, Mikael Søndergaard Thomsen has left the board of directors of CONTERA PHARMA A/S.
About CONTERA PHARMA A/S
CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The board consists of Jae Young Lee (chair), Jee Hun Kim, Paul Ejnar Gremaud Kristjansen and Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802.